Posts Tagged 'topiramate'

Potentially risky diet drug with topiramate unlikely to solve obesity, Economist says

The Economist has published an article challenging the likelihood of new diet drugs reducing obesity rates, despite their risks. One drug in particular is Qysmia, which contains topiramate, the active ingredient in Topamax. Qysmia has been under review by the Food and Drug Administration (FDA) for more than a year.

Read more about the risks associated with topiramate…

European regulators won’t recommend weight loss drug containing Topamax ingredient

The European Medicines Agency (EMA) has recommended not to approve a new weight loss drug that contains topiramate, the active drug in Topamax. The EMA expressed concerns about the long-term risks of cardiovascular problems and other side effects associated with the drug, known as Qsymia.

Read more about the side effects caused by drugs containing topiramate…

FDA-approved diet drug Qsymia now available with prescription

A new diet drug approved by the U.S. Food and Drug Administration in July is now available for obese and at-risk overweight patients. The oral medication Qsymia can only be obtained with a doctor’s prescription. One of the ingredients in Qsymia is topiramate, an anti-convulsant that has been linked to birth defects such as cleft lip and cleft palate in babies born to women who have taken it for migraines or seizures.

Read more about the potential side effects of Qsymia…

FDA Adds Suicide Warning to Epilepsy Drugs

FDA Adds Suicide Warning to Epilepsy DrugsThe U.S. Food and Drug Administration announced Tuesday that it was adding a label warning on heightened suicide risk for users of antiepileptic drugs. The move, which follows the advice last summer of an FDA advisory panel, stops short of slapping the strongest “black box” warning on this class of drugs, which includes widely used medications such as clonazepam (Klonopin), phenytoin (Dilantin) and topiramate (Topamax).

Click here to read more


Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 437 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101

Email: info@hkllp.com

Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.